[1]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651-1653.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
　LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(11):1651-1653.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
点击复制

柴胡疏肝散在肝脏疾病中的应用研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年11期
页码:
1651-1653
栏目:
综 述
出版日期:
2022-11-05

文章信息/Info

Title:
Application of Chihu Shugan powder in liver diseases
作者:
梁瀞云; 唐 燕; 司马玲; 伍漫漫; 廖丹丹; 梁 皓; 陈启帆; 罗伟生
(广西中医药大学,广西 南宁530200)
Author(s):
LIANG Jingyun; TANG Yan; SIMA ling; WU Manman; LIAO Dandan; LIANG Hao; CHEN Qifan; LUO Weisheng
(Guangxi University of Traditional Chinese Medicine,Nanning 530200,China)
关键词:
肝纤维化;  肝癌;  肝硬化;  脂肪肝;  柴胡疏肝散
Keywords:
Liver fibrosis;  Cancer of the liver;  Cirrhosis of the liver;  Fatty liver disease;  Chaihu Shugan powder
分类号:
R 256.4
DOI:
DOI:10.3969/j.issn.1000-7369.2022.11.038
文献标志码:
A
摘要:
柴胡疏肝散出自《景岳全书》,由柴胡、川芎、陈皮、芍药、香附、炙甘草、炒枳壳7味中药组成,其主要功效为疏肝解郁、理气止痛,常用于治疗肝郁气滞引起的两胁肋部疼痛,胸闷善太息,情绪急躁易怒,反酸嗳气,脘腹胀满等。现代药理学研究发现,其组方主要包含皂苷类、黄酮类、酚酸类、萜类四种成分,具有抗炎、镇痛、护肝、抗肿瘤等多种药理作用,应用于各种肝脏疾病中可以有效改善患者症状、体征,改善肝功能、肝纤维化、血脂指标,提高患者生存质量。现从柴胡疏肝散近年来在肝纤维化、肝癌、肝硬化、脂肪肝、慢性胆囊炎等肝脏疾病中的相关应用,对柴胡疏肝散的最新研究动态进行综述,为临床应用柴胡疏肝散治疗肝脏疾病提供依据。
Abstract:
The original formula of Chaihu Shugan powder is composed of 7 main traditional Chinese medicines including cymbidium perfoliatum,ligusticum chuanxiong,tangerine peel,peony,rhizoma cyperi,prepared licorice and fried fructus aurantii.Its main functions are to soothe the liver and relieve depression,regulate Qi and relieve pain.It is often used for the treatment of rib pain,chest tightness and excessive breath,emotional depression and irritability,belching,abdominal distension and fullness.Modern pharmacology study found that the formula contains saponins,flavonoids,phenolic acids,terpenoids,saponins,flavonoids,phenolic acids and other ingredients,has anti-inflammatory and analgesic,protect liver,fall hematic fat,antioxidation,antivirus,antitumor,pharmacological effects,such as in liver disease can effectively improve the patient's symptoms,signs,reduce the liver function and liver fibrosis index,blood lipid index,improve patients' quality of life.This paper reviews the latest research trends of Chaihu Shugan powder in recent years from the relevant application of Chaihu Shugan powder in liver fibrosis,liver cancer,cirrhosis,fatty liver,chronic cholecystitis and other liver diseases,so as to provide more powerful evidence for the effective application of Chaihu Shugan powder in the treatment of liver diseases.

参考文献/References:

[1] 任 鹏,王林林,许飞虹,等.柴胡疏肝散醇提物的抗氧化活性[J].中国实验方剂学杂志,2014,20(10):161-164.
[2] 张爱华,郭姗姗.柴胡的临床运用及药理研究[J].中医研究,2019,32(4):7-9.
[3] 林飞武,王自善,戎 珍,等.柴胡的药理作用化学成分及开发利用研究[J].亚太传统医药,2020,16(10):202-205.
[4] 曹伊媛,陈 颖,周 薏,等.基于网络药理学研究柴胡疏肝散治疗急性胰腺炎的作用机制[J].陕西中医,2020,41(7):994-998.
[5] 赵 红.川芎的鉴定方法及药理分析与临床应用[J].光明中医,2021,36(10):1730-1732.
[6] 黄秀芳,庾国桢,童晶晶,等.基于网络药理学分析陈皮的药理作用机制[J].中成药,2019,41(12):3038-3045.
[7] 高 萌,陈 欢,李焐仪,等.枳壳活性成分与生态因子的相关性[J].中药材,2019,42(11):2508-2512.
[8] 刘 欢,张孟历,于 猛,等.醋制香附挥发油抗抑郁活性及化学成分分析[J].药物评价研究,2020,43(3):436-442.
[9] 徐佳新,许 浚,曹 勇,等.中药白芍现代研究进展及其质量标志物的预测分析[J].中国中药杂志,2021,46(21):5486-5495.
[10] 马晓飞,王喜城,陈 捷,等.甘草治疗肝细胞癌的网络药理分析与潜在机制研究[J].岭南现代临床外科,2020,20(6):703-710.
[11] Ma L,Wei JF,Zeng YL,et al.Mesenchymal stem cell-originated exosomal circ DIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J].Drug Deliv,2022,29(1):440-453.
[12] 田新红,王 琦,尚立芝,等.柴胡疏肝散对肝纤维化大鼠TGF-β1/p38MAPK信号通路的作用及相关性研究[J].中国中医基础医学杂志,2016,22(1):62-65.
[13] 尚立芝,王 付,王 琦,等.柴胡疏肝散对肝纤维化大鼠TGF-β1/Smad信号通路的影响[J].中国实验方剂学杂志,2015,21(12):125-128.
[14] 徐列明,刘 平,沈锡中,等.肝纤维化中西医结合诊疗指南(2019年版)[J].中国中西医结合杂志,2019,39(11):1286-1295.
[15] 吴小溪,汪 涛,杜晟楠,等.7种无创诊断模型对慢性乙型肝炎肝纤维化及肝硬化的诊断价值评估[J].中国医药导报,2022,19(10):14-19.
[16] 李小侠.血清谷氨酸脱氢酶与其他肝功能指标联合检测在肝病诊断中的临床意义[J].陕西医学杂志,2020,49(12):1677-1680.
[17] 赵鹏飞,刘绍能.柴胡疏肝散加减治疗气滞血瘀型肝纤维化疗效观察[J].青海医药杂志,2017,47(7):73-74.
[18] 韩 玫,李 贞,周 舟,等.艾灸联合柴胡疏肝散治疗慢性乙型肝炎肝纤维化[J].中医学报,2021,36(7):1562-1567.
[19] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[20] 刘 丹,王 琮,李牧婵,等.徐春军教授治疗原发性肝癌经验浅析[J].中西医结合肝病杂志,2021,31(9):850-852.
[21] 周河燃,黄 挺.黄挺教授自拟理气健脾方治疗晚期原发性肝癌经验撷萃[J].浙江中医药大学学报,2022,46(4):428-432.
[22] 余 宋,洪 靖,冯秋婷,等.翟笑枫教授辨治肝癌经验撷英[J].中国医药导报,2022,19(10):131-135.
[23] 吴 杨.柴胡疏肝散加减治疗肝癌介入术后肝气郁结型患者的临床疗效观察[D].哈尔滨:黑龙江中医药大学,2019.
[24] 阿依宝塔?努腊勒木.柴胡疏肝散加味治疗肝癌肝郁气滞型癌痛的临床研究[D].乌鲁木齐:新疆医科大学,2018.
[25] 单 姗,赵连晖,马 红,等.肝硬化的定义病因及流行病学[J].临床肝胆病杂志,2021,37(1):14-16.
[26] 李晓阳.中药敷脐联合情志护理在肝硬化顽固性腹水中的应用[J].光明中医,2022,37(8):1475-1477.
[27] 程 波,付开慧,王耀娟,等.中医情志护理结合认知行为干预在降低腰椎间盘突出症患者康复期恐动症中的应用[J].中国实用护理杂志,2020,36(31):2411-2417.
[28] 燕腾飞,曹志群,姚姗姗,等.柴胡疏肝散加减联合肝动脉化疗栓塞术治疗原发性肝癌的临床观察[J].世界中西医结合杂志,2021,16(7):1357-1361.
[29] 仝小玲,张连文.中青年人群非酒精性脂肪肝患病现状及影响因素分析[J].解放军预防医学杂志,2021,39(1):70-72.
[30] 李 勤,谢冰昕,靳 敏,等.从虚郁痰瘀论治2型糖尿病合并非酒精性脂肪肝[J].陕西中医,2020,41(5):653-655.
[31] 苏 伟.柴胡疏肝散治疗肝气郁滞型非酒精性脂肪肝患者的临床效果[J].实用中西医结合临床,2021,21(9):8-9.
[32] 郭丽萍.柴胡疏肝散治疗慢性胆囊炎及对患者胆囊功能炎症因子水平的影响[J].陕西中医,2018,39(7):882-884.
[33] 王同单,赵 文,郭 师.柴胡疏肝散加减联合铝碳酸镁咀嚼片治疗胃食管反流病临床研究[J].新中医,2021,53(16):28-30.

相似文献/References:

[1]邱 勇.桃红四物汤对CCl4诱导肝纤维化小鼠治疗作用及其机制研究[J].陕西中医,2019,(12):1673.
　QIU Yong..Protective effects of Taohong Siwu decoction on CCl4induced hepatic fibrosis model mice[J].,2019,(11):1673.
[2]周 用,左 盼,吴哲骁,等.扶正消瘤方治疗肝动脉化疗栓塞术加经皮肝肿瘤射频消融术后肝癌临床研究*[J].陕西中医,2020,(11):1534.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.005]
　ZHOU Yong,ZUO Pan,WU Zhexiao,et al.Effect of Fuzheng Xiaoliu prescription on patients with liver cancer after TACE plus RFA operation[J].,2020,(11):1534.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.005]
[3]闫芍药,聂会勇,王锁良△.加味双柏散外敷联合耳穴压豆对肝癌介入治疗患者疼痛评分及生活质量影响*[J].陕西中医,2020,(12):1763.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.021]
　YAN Shaoyao,NIE Huiyong,WANG Suoliang..Effects of external application of Jiawei Shuangbai powder auricular acupoint combined with pressing with beans on pain score and quality of life in patients with liver cancer pain undergoing interventional therapy[J].,2020,(11):1763.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.021]
[4]周 翔,顾 达,童 聪,等.鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究[J].陕西中医,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
　ZHOU Xiang,GU Da,TONG Cong,et al.Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4[J].,2022,(11):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
[5]胡哲君,汤穆浛,张 锐,等.基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响[J].陕西中医,2024,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
　HU Zhejun,TANG Muhan,ZHANG Rui,et al.Effect of Xiaoyao powder on ferroptosis of hepatic stellate cells in rats with liver fibrosis based on the theory of “treating liver by nourishing spleen”[J].,2024,(11):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
[6]牛丽娜,窦 婧,马 燕,等.和血柔肝方通过PI3K/Akt/NF-κB信号通路调控自噬相关蛋白改善大鼠肝纤维化机制研究[J].陕西中医,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
　NIU Lina,DOU Jing,MA Yan,et al.Mechanism of Hexue Rougan decoction in relieve liver fibrosis in rats by regulating autophagy-related proteins through PI3K/Akt/NF-κB signaling pathway[J].,2024,(11):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
[7]俞佳雯,周 薏,林天龙(加拿大),等.乙肝肝纤维化中西医研究进展[J].陕西中医,2025,46(2):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]
　YU Jiawen,ZHOU Yi,LIN Tianlong,et al.Progress of traditional Chinese and Western medicine research on chronic hepatitis B hepatic fibrosis[J].,2025,46(11):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82160834); 全国名老中医药专家传承工作室建设项目[国中医药人教函(2021)75号]; 广西中医药大学自治区级硕士研究生科研创新项目(YCSW2022344)
更新日期/Last Update: 2022-11-09